WIRE — Novo Nordisk will launch a more affordable authorised copy of its Ozempic diabetes drug in South Africa later this month, partnering with healthcare company Acino to expand patient access. The medicine, which uses the same semaglutide active ingredient as Ozempic, will launch on July 27 and is registered by the South African Health Products Regulatory Source
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.